Poster Presentation 

  

ABSTRACT ID
20230052
NAME
Dr. Yawen Guo
Type of Research
Original Research
Category
Treatment Strategies and Interventions
abAuthors
Yawen Guo# Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China#Yes#Changtian Yin#Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China#No#Yanting Duan#Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China#No#Minghua Ge#Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China#No#Chanming Zheng#Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China#No
Title
Identification and Evaluation of the Functions of Xiangshaliujunzi decoction in Thyroid Cancer Treatment through Network Pharmacology
Abstract

Objectives: Xiangshaliujunzi (XSLJZ) decoction, a well-known traditional Chinese medicine (TCM) formula widely recognized for its effectiveness in cancer treatment, has exhibited favorable clinical therapeutic effects on thyroid cancer. However, the specific active constituents and the molecular mechanisms of action remain unclear.

Methods: In this study, we collected the active ingredients of XSLJZ through Traditional Chinese Medicine Systems Pharmacology (TCMSP). TTD, DrugBank, OMIM, DisGENET, TCGA, and GEO databases were used to search for disease targets of thyroid cancer. STRING platform was used to draw the protein-protein interaction network (PPI). The intersected targets were analyzed by GO and KEGG in R language. Molecular docking validation was performed using PyMOL 2.5.0, AutoDock Tools 1.5.6 and AutoDock Vina 1.1.2 software. The cell killing effect of XSLJZ on human thyroid cancer cell lines 8505c and TPC-1 was verified in vitro using CCK8, Transwell, Flow and WesternBlot. Finally, the tumor suppressive effect of XSLJZ on thyroid cancer was validated in vitro and in vivo using the 8505c cell line in nude mice. 


Results: We identify and evaluate the active constituents of XSLJZ, PPI network was established, targeting drug-disease interactions, and the top 70 target genes were screened. We subsequently validated XSLJZ and its active 5 constituents at the cellular level and found that XSLJZ and its active constituents inhibited proliferation and metastasis, while promoting apoptosis and pyroptosis in 8505C and TPC-1 cell lines. GO and KEGG pathway enrichment analysis and molecular docking results revealed that the mechanism involved in XSLJZ treatment of thyroid cancer may be related to the AGE-RAGE-PI3K-Akt signaling pathway. These results were further confirmed in vivo and in vitro experiments.

Conclusions: Taken together, our study uncovered the active constituents and underlying molecular mechanisms of XSLJZ in thyroid cancer, offering an attractive TCM strategy for thyroid cancer treatment.
BACK